A recent MedTechDive article noted that Johnson & Johnson is splitting its business into two distinct divisions. The company will separate its consumer health division into a new publicly traded company. The brands that will make the move include Tylenol, Listerine, and Band-Aid. The prescription drug and medical device units will continue to run with its current leadership in place. However, the new company, which still doesn’t have a name, will assign a new executive team to lead it. CEO Alex Gorsky will step down from his position at the end of the year and become executive chairman, and Joaquin Duato will succeed him.
J&J Splits Consumer Brand From Pharma and Med Device
The world’s biggest drugmaker is reorganizing its divisions in hopes of boosting the value of its core business.
Nov 19, 2021
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now